Coming Off a GLP-1: What the First Three Months Look Like
Medically reviewed by Dr. Scott Gmora, MD, FRCSC, FACSLast reviewed
Appetite returns before the weight does. For most people stopping semaglutide, tirzepatide or liraglutide, the earliest change is not the number on the scale — it is the return of hunger and of food-related thoughts as blood levels of the medication fall, which for a weekly injection takes weeks rather than days. Weight follows later, more gradually, along a curve that is steepest at the start and then flattens.
The three months after a last dose have a fairly predictable shape. Almost everything in them is pharmacology working exactly as pharmacology does, not a person coming undone.
Stopping is common, and it is not a failure of willpower
Discontinuation within the first year is the norm rather than the exception. A Danish nationwide registry cohort of 77,310 adults found 52% had stopped semaglutide prescribed for weight loss within twelve months, 18% of them by three months — figures presented at a conference in September 2025 and not yet peer-reviewed. The reasons recorded most often are side effects, cost and supply. One real-world analysis put side effects at 28.2% and cost or affordability at 12.8%, with drug unavailability peaking at 14.6% during the 2023–24 shortage. A clinic-based cohort ranked them the other way round, with cost or insurance at 47.6% ahead of intolerable side effects at 14.6% and shortages at 11.8%. The two datasets disagree on which reason leads. Whichever does, those are circumstances, not character.
What follows a stop is not evidence the treatment was wasted either. Obesity behaves as a chronic condition, and body weight is actively defended: when weight falls, appetite signalling and energy expenditure both shift in the direction of restoring it. That is why Health Canada approved semaglutide 2.4 mg for chronic weight management, as an adjunct to diet and activity rather than as a course of treatment with a finish line. Canada's obesity guidelines say it plainly: pharmacotherapy should be continued long term when it is working, because trials consistently show weight regain and regression of the associated health benefits once it stops, even where behaviour change continues.
Regain is written into the pharmacology. It is not written into the patient.
How long the medication actually stays in your system
Half-life is the time it takes for the concentration in the blood to fall by half. A drug is largely cleared after roughly five half-lives.
| Medication | Elimination half-life | Largely cleared after |
|---|---|---|
| Semaglutide 2.4 mg (weekly) | about 1 week | about 7 weeks |
| Tirzepatide (weekly) | about 5–6 days | about 3–4 weeks |
| Liraglutide 3.0 mg (daily) | about 13 hours | about 2–3 days |
Half-life figures: Health Canada-authorized product monographs for semaglutide 2.4 mg (Wegovy), tirzepatide, and liraglutide 3.0 mg (Saxenda).
The monographs are the more precise guide, and for semaglutide the Canadian one is more conservative than the five-half-life rule of thumb: the drug can be present in the circulation for approximately seven weeks after a last 2.4 mg dose.
So the week or two after a final weekly dose can feel deceptively unchanged: the medication is still there and still working. What comes next is a fade rather than a switch being flipped — which is why people sometimes conclude at week six or seven that something has gone wrong with them, when what actually happened is that a drug finished leaving.
There is no established tapering protocol. Current guidelines make no specific recommendation on dose tapering or structured maintenance after these medications; it is an acknowledged research gap rather than a settled question. Whether to taper, over what period, and whether to stop at all are decisions for the prescriber.
Weeks 1 to 4: the quiet gets louder
GLP-1 medications act on receptors in the hypothalamus, brainstem and mesolimbic reward pathways — the circuits governing hunger, satiety, and how rewarding food feels. That effect depends on drug concentration at the receptor, so it fades as concentration falls. Appetite moves on the timetable above, not on a timetable anyone chooses.
Many people describe what returns as food noise: persistent, intrusive, rumination-like thoughts about food that are unwanted or distressing and show up whether or not the stomach is empty. It is not a formal diagnosis, though researchers published a working definition in 2025. Hearing it start up again after months of quiet is unsettling. It is also expected, and it is not a relapse.
The second change in this window runs the other way. Nausea, reflux, constipation and uncomfortable early fullness typically ease as the drug clears. Feeling physically better and hungrier at the same time is disorienting, and common.
Weeks 4 to 8: hunger, portions, and how food feels
Peripherally, these medications slow gastric emptying, which contributes to feeling full sooner and staying full longer. One nuance changes what to expect. With long-acting weekly agents, the slowing of gastric emptying attenuates over months of continuous use as the receptor response desensitises, while shorter-acting agents retain more of it. Someone who has been on a weekly medication for a year may notice less change in how quickly food leaves the stomach than they were bracing for. The larger shift is in appetite and satiety, driven centrally.
Portion size is where this becomes practical. Energy requirements fall after weight loss — a smaller body costs less to run — so the portions that held weight steady at month ten of treatment will not hold it steady at week six off treatment. That is arithmetic, not indiscipline. It is also worth understanding what it means when a GLP-1 stops working as well as it did, because the two situations can feel similar from the inside.
Weeks 8 to 12: what the scale actually does
Regain after stopping is well documented, and it is not linear.
In the extension of the STEP 1 trial, participants who had lost a mean of 17.3% of body weight over 68 weeks on semaglutide 2.4 mg regained about two-thirds of it in the year after treatment stopped, finishing 5.6% below their starting weight on average; improvements in blood pressure and lipids largely reverted toward baseline. Tirzepatide withdrawal in SURMOUNT-4 followed a comparable pattern: after a 36-week lead-in on the drug, participants switched to placebo regained weight while those who continued kept losing.
For anyone standing in month two, the shape matters more than the endpoint. A 2026 meta-regression of six randomised trials modelled it: regain is fastest immediately after stopping and then decelerates, with roughly 60% of lost weight back at one year and a modelled plateau near three-quarters — still below pre-treatment weight. The first three months sit on the steep part of that curve, so early movement is not a preview of the slope continuing at the same angle.
Real-world figures are often gentler. A 2026 analysis of 7,938 patients found those treated for obesity had lost 8.4% on average before stopping and regained only 0.5% a year later — but 35.2% received another obesity treatment within twelve months (27.4% another medication, 13.7% lifestyle-modification visits, 0.6% bariatric surgery), and 19.6% restarted the medication they had stopped. Which is the honest headline: what happens after stopping depends heavily on what comes next. These are group averages with wide variation — tendencies, not a forecast for any one person. If you want the mechanism in more depth, see weight regain after stopping a GLP-1.
Expected physiology, and reasons to call
| Expected in the first three months | Worth contacting your prescriber about |
|---|---|
| Appetite and food-related thoughts returning over weeks | Rising blood glucose in type 2 diabetes; other diabetes medications may need review |
| Nausea, reflux and constipation easing | Blood pressure or cholesterol drifting back up, since these tend to revert after stopping |
| Some weight regain, fastest early and slowing later | Weight climbing faster than expected, or past your starting point |
| Needing smaller portions than felt normal on treatment | Distress, bingeing or loss of control around food, particularly with any history of disordered eating |
| Energy and mood fluctuating as intake changes | Persistent vomiting, severe abdominal pain or dehydration, which are not features of stopping |
| Wondering whether to restart | Having stopped because of cost, supply or side effects, since alternatives may exist |
Restarting the same medication, changing dose, or switching class — to another GLP-1 receptor agonist, or to something like naltrexone–bupropion — are legitimate outcomes rather than concessions (options if a GLP-1 is not the right fit right now). That conversation can happen at The Sleeve Clinic, which prescribes and co-manages weight-management medication as well as performing sleeve gastrectomy. Nothing here should be used to start, stop, taper or change the dose of any medication. Those decisions sit with the prescriber, who has the full history.
Two things worth doing while this plays out
Keep measuring something — weight, waist, or whatever a clinician already tracks. A trend caught at week four is easier to act on than one noticed at month six, and the steep part of the curve is where a measurement carries the most information.
Protect muscle. Canada's obesity guidelines note that resistance training may promote weight maintenance and modest gains in muscle, fat-free mass and mobility, and that 30 to 60 minutes of moderate-to-vigorous aerobic activity most days can be considered to favour weight maintenance after weight loss — both graded as moderate-strength evidence rather than certainty. Adequate protein serves the same goal, and the same guidelines favour eating patterns a person can sustain over ones that produce faster numbers — which argues against answering a difficult month with a severe diet.
Where surgery fits, and where it does not
Most people who come off a GLP-1 do not go on to have surgery, and do not need to — in the real-world data above, the common next steps were restarting, switching, or adding structured support.
Bariatric surgery is one option among several, suitable for some people and not others, and only after individual assessment. Sleeve gastrectomy acts on the same appetite and satiety physiology from a different direction, which is why the trade-offs are worth understanding properly rather than as a contest (how weight-loss medications and bariatric surgery compare). Medication is not a separate errand: The Sleeve Clinic prescribes and co-manages weight-management medication, so staying on it, restarting it or changing to something else can be worked through with the clinic. Surgery is one possible answer to this question, not the intended one.
At The Sleeve Clinic in Toronto, sleeve gastrectomy is private-pay in Ontario and is not funded by OHIP (pricing and financing). Surgical candidacy is determined in assessment, not from a website, and for someone whose weight has already fallen on a GLP-1 that assessment looks at current BMI, the highest documented BMI, and the trajectory across both. What sleeve gastrectomy involves · eligibility criteria
Common questions
Will appetite come back all at once?
Usually not. It tracks falling drug levels, fading in over days for a daily medication and over several weeks for a weekly one.
How long before the medication is out of my system?
About seven weeks for semaglutide 2.4 mg, which its Canadian monograph says can remain in the circulation that long after a final dose. Roughly five half-lives covers the others: three to four weeks for tirzepatide, and two to three days for liraglutide 3.0 mg.
Do I need to taper?
There is no established tapering protocol and current guidelines do not specifically recommend one. Some prescribers taper regardless. That is a conversation for the clinician who prescribed the medication.
I stopped because of cost or supply, not because I wanted to. Does that change anything?
It changes the conversation, not the physiology. A prescriber may be able to discuss different agents, doses, or coverage pathways. See also: coverage and cost questions around GLP-1 medications.
I am still taking a GLP-1 and have surgery or an endoscopy booked. What should I do?
Tell the surgical and anaesthesia team well in advance. Multi-society guidance issued in 2024 by anaesthesia, gastroenterology and metabolic surgery organisations advises that most patients can continue these medications before elective procedures, with additional precautions such as a 24-hour liquid diet for those at higher risk of retained gastric contents. That is the general position, and individual centres are free to set a stricter one. The Sleeve Clinic does: patients having surgery here stop the GLP-1 at least two weeks before the operating date. The clinic's instruction is the more conservative of the two, and it is the one that applies to surgery at The Sleeve Clinic. For a procedure booked with any other team, follow the instructions that team gives you. More answers of this kind live on our FAQ page.
If you are somewhere in these three months
The first twelve weeks off a GLP-1 are mostly a drug leaving and a body responding the way bodies respond. Knowing the shape of that — appetite first, weight later, steepest early and then flatter — makes it easier to read what is happening without reading it as personal failure. Individual results vary. Consult with Dr. Gmora for a personalized assessment.
This article is general education about a common clinical situation. It is not medical advice, it does not create a physician–patient relationship, and it cannot account for an individual's history, medications or risk profile. Decisions about starting, continuing, tapering or stopping any weight-management medication belong with the prescribing clinician, and severe or persistent symptoms warrant assessment rather than waiting.
If medication or surgery is one of the options being weighed, a consultation is a place to ask what each involves, what neither solves, and whether either is a reasonable fit — with no obligation to proceed. The Sleeve Clinic prescribes and co-manages weight-management medication as well as performing sleeve gastrectomy, so someone who has come off a GLP-1 and has no interest in an operation still has somewhere to take the question. When you're ready, book a consultation · about the surgeon
The Sleeve Clinic — Toronto, Ontario. Dr. Scott Gmora, MD FRCSC FACS.
Considering gastric sleeve?
Explore these resources to take the next step.
You May Also Be Interested In
Restarting a GLP-1 After a Break: Does It Work the Same?
Stopping and restarting a GLP-1 is common. What re-titration usually involves, what the evidence says about response the second time, and who decides it.
Read Article
Food Noise After Stopping a GLP-1: Why Hunger Returns
Food noise and hunger usually return after stopping a GLP-1. Here is why that happens, how fast it starts, why it can feel louder, and what actually helps.
Read Article
How to Keep Weight Off After Stopping a GLP-1 Medication
Stopping a GLP-1 often brings some weight back. What the evidence says about protein, training, sleep and follow-up — and what to do if they aren't enough.
Read Article